These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19966776)

  • 1. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.
    Cerchietti LC; Lopes EC; Yang SN; Hatzi K; Bunting KL; Tsikitas LA; Mallik A; Robles AI; Walling J; Varticovski L; Shaknovich R; Bhalla KN; Chiosis G; Melnick A
    Nat Med; 2009 Dec; 15(12):1369-76. PubMed ID: 19966776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
    Gallerne C; Prola A; Lemaire C
    Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.
    Cerchietti LC; Hatzi K; Caldas-Lopes E; Yang SN; Figueroa ME; Morin RD; Hirst M; Mendez L; Shaknovich R; Cole PA; Bhalla K; Gascoyne RD; Marra M; Chiosis G; Melnick A
    J Clin Invest; 2010 Dec; 120(12):4569-82. PubMed ID: 21041953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
    Usmani SZ; Bona RD; Chiosis G; Li Z
    J Hematol Oncol; 2010 Oct; 3():40. PubMed ID: 20977755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.
    Lee Y; Li HK; Masaoka A; Sunada S; Hirakawa H; Fujimori A; Nickoloff JA; Okayasu R
    Radiother Oncol; 2016 Oct; 121(1):162-168. PubMed ID: 27666928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.
    Abramson JS; Chen W; Juszczynski P; Takahashi H; Neuberg D; Kutok JL; Takeyama K; Shipp MA
    Br J Haematol; 2009 Feb; 144(3):358-66. PubMed ID: 19036086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
    Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
    Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90.
    Kuai Y; Gong X; Ding L; Li F; Lei L; Gong Y; Liu Q; Tan H; Zhang X; Liu D; Ren G; Pan H; Shi Y; Berberich-Siebelt F; Mao Z; Zhou R
    Cell Commun Signal; 2018 Aug; 16(1):50. PubMed ID: 30143009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of germinal center B-cell lymphoma in archival specimens: critical evaluation of Bcl-6 protein expression in diffuse large B-cell lymphoma of the tonsil.
    Ree HJ; Ohsima K; Aozasa K; Takeuchi K; Kim CW; Yang WI; Huh JY; Lee SS; Ko YH; Kwon MS; Cho EY; Choi YL; Rhee JC; Kikuchi M; Mori S
    Hum Pathol; 2003 Jun; 34(6):610-6. PubMed ID: 12827616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma.
    Ree HJ; Yang WI; Kim CW; Huh J; Lee SS; Cho EY; Ko YH; Charney D
    Hum Pathol; 2001 Sep; 32(9):954-62. PubMed ID: 11567225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.
    Taldone T; Zatorska D; Ochiana SO; Smith-Jones P; Koziorowski J; Dunphy MP; Zanzonico P; Bolaender A; Lewis JS; Larson SM; Chiosis G; Pillarsetty NV
    J Labelled Comp Radiopharm; 2016 Mar; 59(3):129-32. PubMed ID: 26806023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.
    Segawa T; Fujii Y; Tanaka A; Bando S; Okayasu R; Ohnishi K; Kubota N
    Int J Mol Med; 2014 Mar; 33(3):559-64. PubMed ID: 24366006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
    Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
    Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical evaluation of Bcl-6 protein expression in diffuse large B-cell lymphoma of the stomach and small intestine.
    Kwon MS; Go JH; Choi JS; Lee SS; Ko YH; Rhee JC; Ree HJ
    Am J Surg Pathol; 2003 Jun; 27(6):790-8. PubMed ID: 12766583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.
    Nayar U; Lu P; Goldstein RL; Vider J; Ballon G; Rodina A; Taldone T; Erdjument-Bromage H; Chomet M; Blasberg R; Melnick A; Cerchietti L; Chiosis G; Wang YL; Cesarman E
    Blood; 2013 Oct; 122(16):2837-47. PubMed ID: 23943653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.
    Caldas-Lopes E; Cerchietti L; Ahn JH; Clement CC; Robles AI; Rodina A; Moulick K; Taldone T; Gozman A; Guo Y; Wu N; de Stanchina E; White J; Gross SS; Ma Y; Varticovski L; Melnick A; Chiosis G
    Proc Natl Acad Sci U S A; 2009 May; 106(20):8368-73. PubMed ID: 19416831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.
    Ambati SR; Lopes EC; Kosugi K; Mony U; Zehir A; Shah SK; Taldone T; Moreira AL; Meyers PA; Chiosis G; Moore MA
    Mol Oncol; 2014 Mar; 8(2):323-36. PubMed ID: 24388362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy of BCL6-dependent diffuse large B-cell lymphomas by heat-shock protein 90 inhibition.
    Briones J
    Expert Rev Hematol; 2010 Apr; 3(2):157-9. PubMed ID: 21083459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities.
    Skinnider BF; Horsman DE; Dupuis B; Gascoyne RD
    Hum Pathol; 1999 Jul; 30(7):803-8. PubMed ID: 10414499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.